AGMB-129 is under clinical development by AgomAb Therapeutics and currently in Phase II for Crohn’s Disease (Regional Enteritis). According to GlobalData, Phase II drugs for Crohn’s Disease (Regional Enteritis) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AGMB-129’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AGMB-129 is under development for the treatment of crohn's disease. It is administered orally as a capsule. The drug candidate acts by targeting ALK5.
It was under development for colon cancer.
AgomAb Therapeutics overview
AgomAb Therapeutics (AgomAb) is a biotechnology company that develops growth factor mimetic agonistic monoclonal antibodies to regenerate damaged tissues and produced a comprehensive preclinical package. The company product pipeline includes AGMB -129, AGMB -447, AGMB -101 and AGMB -101. Its pipeline treats to cronh’s disease, idiopathic pulmonary fibrosis, organ failure and fibrotic indication. AgomAb provides novel treatment to restore organ functions. The company combines new scientific insights with robust drug development and build a broad clinical pipeline of differentiated programs with disease-modifying potential in severe organ failure and fibrotic diseases. The company operates its research laboratory in Italy and Spain. AgomAb is headquartered in Ghent, Belgium.
For a complete picture of AGMB-129’s drug-specific PTSR and LoA scores, buy the report here.